These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 17600475)

  • 1. Translation of dosimetric results of preclinical radionuclide therapy to clinical situations: influence of photon irradiation.
    Uusijärvi H; Bernhardt P; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2007 Apr; 22(2):268-74. PubMed ID: 17600475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
    Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
    Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.
    Uusijärvi H; Bernhardt P; Rösch F; Maecke HR; Forssell-Aronsson E
    J Nucl Med; 2006 May; 47(5):807-14. PubMed ID: 16644751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical animal research on therapy dosimetry with dual isotopes.
    Konijnenberg MW; de Jong M
    Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S19-27. PubMed ID: 21484379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-energy electron emitters for targeted radiotherapy of small tumours.
    Bernhardt P; Forssell-Aronsson E; Jacobsson L; Skarnemark G
    Acta Oncol; 2001; 40(5):602-8. PubMed ID: 11669332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions.
    Lanconelli N; Pacilio M; Lo Meo S; Botta F; Di Dia A; Aroche AT; Pérez MA; Cremonesi M
    Phys Med Biol; 2012 Jan; 57(2):517-33. PubMed ID: 22217735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy.
    Emfietzoglou D; Kostarelos K; Sgouros G
    J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration.
    Bernhardt P; Ahlman H; Forssell-Aronsson E
    Med Phys; 2004 Sep; 31(9):2628-35. PubMed ID: 15487746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorbed fractions for photons in ellipsoidal volumes.
    Amato E; Lizio D; Baldari S
    Phys Med Biol; 2009 Oct; 54(20):N479-87. PubMed ID: 19779222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
    Timmermand OV; Tran TA; Strand SE; Axelsson J
    J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions.
    Bouchet LG; Bolch WE; Goddu SM; Howell RW; Rao DV
    J Nucl Med; 2000 Apr; 41(4):682-7. PubMed ID: 10768569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes.
    Stabin MG; Konijnenberg MW
    J Nucl Med; 2000 Jan; 41(1):149-60. PubMed ID: 10647618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production and dosimetric aspects of the potent Auger emitter 58mCo for targeted radionuclide therapy of small tumors.
    Thisgaard H; Elema DR; Jensen M
    Med Phys; 2011 Aug; 38(8):4535-41. PubMed ID: 21928624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
    Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
    J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact on 141Ce, 144Ce, 95Zr, and 90Sr beta emitter dose coefficients of photon and electron SAFs calculated with ICRP/ICRU reference adult voxel computational phantoms.
    Li WB; Zankl M; Schlattl H; Petoussi-Henss N; Eckerman KF; Bolch WE; Oeh U; Hoeschen C
    Health Phys; 2010 Oct; 99(4):503-10. PubMed ID: 20838091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
    Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V
    J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
    Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
    Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.